AcelRx Pharmaceuticals (ACRX) – Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of AcelRx Pharmaceuticals (NASDAQ: ACRX) in the last few weeks:

  • 8/9/2017 – AcelRx Pharmaceuticals was upgraded by analysts at Stifel Nicolaus from a “hold” rating to a “buy” rating.
  • 8/4/2017 – AcelRx Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.
  • 8/4/2017 – AcelRx Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician’s office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. “
  • 8/2/2017 – AcelRx Pharmaceuticals was given a new $13.00 price target on by analysts at Roth Capital. They now have a “buy” rating on the stock.
  • 8/1/2017 – AcelRx Pharmaceuticals was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 8/1/2017 – AcelRx Pharmaceuticals had its “hold” rating reaffirmed by analysts at Cowen and Company.
  • 7/25/2017 – AcelRx Pharmaceuticals was given a new $3.00 price target on by analysts at Piper Jaffray Companies. They now have a “hold” rating on the stock.
  • 7/24/2017 – AcelRx Pharmaceuticals was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 7/14/2017 – AcelRx Pharmaceuticals had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $7.00 price target on the stock.
  • 7/11/2017 – AcelRx Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician’s office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. “

AcelRx Pharmaceuticals, Inc. (NASDAQ ACRX) opened at 3.00 on Thursday. The firm has a 50-day moving average of $2.70 and a 200-day moving average of $2.77. AcelRx Pharmaceuticals, Inc. has a 1-year low of $1.95 and a 1-year high of $4.08. The firm’s market capitalization is $136.14 million.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its earnings results on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by $0.01. The business had revenue of $2.66 million for the quarter, compared to analyst estimates of $2.63 million. AcelRx Pharmaceuticals had a negative return on equity of 478.66% and a negative net margin of 319.19%. On average, analysts expect that AcelRx Pharmaceuticals, Inc. will post ($1.13) earnings per share for the current year.

In other AcelRx Pharmaceuticals news, major shareholder Life Sciences Maste Perceptive sold 875,000 shares of the stock in a transaction on Monday, June 19th. The shares were sold at an average price of $2.40, for a total transaction of $2,100,000.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 28.10% of the stock is currently owned by corporate insiders.

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Receive News & Ratings for AcelRx Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply